Investment Fund Reduces Stake in Biotech Ahead of FDA Decision
A fund has notably decreased its investment in a biotech company by $7 million, coinciding with an important FDA decision scheduled for June 30.
Browse the full archive, newest first.
A fund has notably decreased its investment in a biotech company by $7 million, coinciding with an important FDA decision scheduled for June 30.
A look into the potential trajectories for Palantir Technologies over the next ten years reveals both optimistic and pessimistic scenarios.
As geopolitical tensions rise, market analysts are paying close attention to oil prices and yields, with Trump highlighting the urgency of the situation in Iran. Nvidia's upcoming earnings report is also on investors' radar.
A recent outbreak of a rare hantavirus strain on a cruise ship is reminiscent of the COVID-19 pandemic, leading to the resurgence of various conspiracy theories.
Short-form videos are being explored as a potential tool for enhancing the teaching of small-engine maintenance skills, reflecting a shift in educational methods.